Article Text

other Versions

PDF
Orthovoltage radiotherapy in the management of medial canthal basal cell carcinoma
  1. Hatem Krema1,
  2. Evelyn Herrmann2,
  3. Alisha Albert-Green3,
  4. David Payne2,
  5. Normand Laperriere2,
  6. Caroline Chung2
  1. 1Ocular oncology Service, Department of Ophthalmology and Vision Sciences, Princess Margaret Hospital/UHN, University of Toronto, Toronto, Ontario, Canada
  2. 2Department of Radiation Oncology, Princess Margaret Hospital/UHN, University of Toronto, Toronto, Ontario, Canada
  3. 3Department of Biostatistics, Princess Margaret Hospital/UHN, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr Hatem Krema, Ocular Oncology Service 18-739, University of Toronto, Princess Margaret Hospital, 610 University Avenue, Toronto, ON M5G 2M9, Canada; htmkrm19{at}yahoo.com

Abstract

Aims To report the local control and complication rates of orthovoltage radiotherapy in the management of medial canthal basal cell carcinoma (BCC).

Methods The medical records of all patients treated with medial canthal BCC between 1998 and 2010, with orthovoltage radiotherapy as primary treatment, adjuvant treatment after incomplete surgical excision, or for tumour recurrence following surgical excision, were retrospectively studied. The actuarial rates of tumour control and complications were calculated using Kaplan–Meier estimates. Main outcome measures were rates of tumour control and radiation complications.

Results 90 patients were included with a median follow-up of 80 months. Tumour control rate at 10 years for the entire cohort was 94% (95% CI 84% to 98%). Tumour control rates showed no statistically significant differences among different treatment intents or treatment radiation energies. Radiation-related complication rates included loss of eyelashes in 59% (95% CI 48% to 66%), epiphora 51% (95% CI 39% to 62%), dry eye 14% (95% CI 3% to 35%) and conjunctival scarring 11% (95% CI 1% to 33%). No patient developed long-term corneal complications.

Conclusions Orthovoltage radiotherapy can be a reliable therapeutic alternative for selected medial canthal BCCs, which can be contained within the prescribed radiation field, with anticipated radiation-related toxicities.

  • Eye Lids
  • Neoplasia
  • Treatment other

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.